Peer-influenced content. Sources you trust. No registration required. This is HCN.

Cleveland Clinic Journal of MedicineFast Onset of Action with Valbenazine for Treatment of Chorea Associated with Huntington Disease

The monoamine transporter 2 inhibitor improved chorea symptoms as early as week 2.

A recent study presented at the International Congress of Parkinson’s Disease and Movement Disorders® has shed light on the potential of valbenazine, a vesicular monoamine transporter 2 inhibitor, in the treatment of chorea associated with Huntington disease (HD). The study reveals that valbenazine not only improves chorea symptoms but also does so as early as week 2, showcasing a fast onset of action.

Key Points

  • The study was led by Raja Mehanna, MD, from the University of Texas Health Science Center.
  • The research involved an indirect comparison of data from clinical trials in adults with HD.
  • Both valbenazine and deutetrabenazine, another vesicular monoamine transporter 2 inhibitor, were found to have a therapeutic effect during the maintenance phase.
  • Deutetrabenazine is currently approved by the US Food and Drug Administration (FDA) for the treatment of chorea associated with HD, while valbenazine is under FDA review for this indication.
  • The phase 3 trials of valbenazine (KINECT-HD) and deutetrabenazine (First-HD) showed significant improvements in chorea with active treatment versus placebo.

According to the Huntington’s Disease Society of America, approximately 30,000 Americans have HD.

More on Movement Disorders

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form